To complement the publication of the 2019 CMTA Annual Report, the Youth of the CMTA created this highlight reel in celebration of all we accomplished together in 2019!
- 2024 CMTA Patient & Research Summit Registration is Now Open
- Advancements in CMT1A and CMT1B Research Highlight CMTA’s Impact
- Advancing the Understanding of CMT2A and CMT2F: A Call to Beat CMT
- Alliance Partner NMD Pharma A/S Launches Phase II SYNAPSE-CMT Trial with First Patient Dosed at CMTA Center of Excellence
- Breakthrough in CMT1A Research: Community Efforts Drive Success of Dental Stem Cell Model
- Bruce R Conklin, MD Joins the CMTA STAR Advisory Board
- Chris Oviatt – Golfer with CMT
- CMT2F Natural History Study Nears Full Recruitment as Biomarker Analysis Begins
- CMT2S Breakthrough
- CMTA Alliance Partner Applied Therapeutics Plans to Submit an NDA for CMT-SORD, a Potential First Approval for the Treatment of any type of CMT
- CMTA Alliance Partner, Applied Therapeutics, Announces Positive 12-Month Results in its Ongoing INSPIRE Phase III Trial for CMT-SORD
- CMTA and INC Forge Groundbreaking Alliance to Accelerate Comprehensive Research Across All Charcot-Marie-Tooth Disease Types
- CMTA Announces New Center of Excellence at Duke University Hospital
- CMTA Announces New Center of Excellence at Virginia Commonwealth University
- CMTA Announces New Center of Excellence in Indianapolis
- CMTA Announces New Center of Excellence in Kentucky
- CMTA Announces New Center of Excellence in Thailand
- CMTA Announces New Center of Excellence in the United Kingdom
- CMTA Appoints David Skarinsky to its Therapy Expert Board
- CMTA Appoints Katherine Forsey Chief Research Officer
- CMTA Appoints Science and Technology Veteran, Patricia Verduin, PhD, to the Board of Directors
- CMTA Partners with Actio Bio on CMT2C Focus Group
- CMTA Supports the Accelerating Kids’ Access to Care Act (H.R.4758 / S.2372)
- CMTA-INC Strategic Alliance Announces the 2025 Inherited Neuropathy Fellowship
- CMTA-STAR Alliance Partner Actio Biosciences Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Their Treatment in Development for CMT2C
- CMTA-STAR Alliance Partner NMD Pharma Publishes Transformative Study on Charcot-Marie-Tooth Disease
- CMTA-STAR Collaboration Celebrates a Decade of CMT Genetic Discovery Through the GENESIS Database
- CMTA’s $240K Investment Targets Gene Replacement Therapy in CMT4 Subtypes
- CMTA’s Strategic Investment Advances Research for CMT1A and CMT1B
- CMTA’s CRISPR Research Initiative Advances for CMT1A and CMT1B
- Diana Bharucha-Goebel, MD Joins the CMTA-STAR Advisory Board
- DNA-Based Therapeutics: A Promising Future for CMT2E Treatment
- Exploring New Therapeutic Pathways for CMT1B: UPR Activation
- From Gene Discovery to Gene Editing: Closing the Diagnostic Gap and Developing CRISPR/Cas9 Capabilities in CMT
- Gene Replacement Therapy in CMT4 Subtypes
- Gene Therapy for CMT1A, 1B, and X1: Progress in Nanoparticles
- Leading the Way: The CMTA Invests More Than $200K in Cutting-Edge CMT1A Organoid Research
- Mindset Strategies for Kids and Teens with CMT
- Nanoparticles for CMT1A, CMT1B, and CMTX1: A New Frontier in Gene Therapy
- New Law Makes Flying Easier for People Living With Charcot-Marie-Tooth Disease
- NMD Pharma Receives FDA Approval to Initiate Phase II Clinical Trial of NMD670 in CMT Patients
- Progress Update: Timmerman’s CMT1A Organoid Project Shows Early Success
- Recap: 2024 CMTA Patient & Research Summit
- Repurposing Drugs for CMT1A: An Encouraging Approach
- TAKE ACTION! Sign the Petition to Accelerate CMT-SORD
- The Charcot-Marie-Tooth Association Launches Gadget Store
- The CMTA Appoints Professor Charlotte Sumner, M.D., to its Scientific Advisory Board
- The CMTA Mourns the Loss of Scientific Advisory Board Member and Esteemed CMT Clinical Researcher
- Vera Fridman, MD joins the CMTA STAR Advisory Board
- Swag Up for CMT Awareness Month!
- Employment Opportunities at the CMTA
- Pete Foley Joins CMTA Board of Directors
- The Summer 2021 CMTA Report
- The Spring 2021 CMTA Report – Special Research Edition
- CMTA-STAR Awards $1.1 Million for CMT1X, CMT2A Clinical Trials
- Faces of CMT Photography Competition
- The Winter 2020-2021 CMTA Report
- Who Inspires You to Give?
- The Fall 2020 CMTA Report
- CMTA and Pharnext Enter Biomarker Research Collaboration
- CMT Awareness Month 2020: Be a Champion
- Type 2 Update: One Patient’s Diagnostic Odyssey with SORD
- The 2020 Summer CMTA Report
- Breakthrough Guide to Orthopedic Surgery for CMT
- CMTA Camp Footprint Has Gone Virtual for 2020
- CMTA 2019 Annual Report Highlight Reel
- Craig Zeltsar Joins CMTA Board of Directors
- New, Potentially Treatable, Type of CMT Discovered
- CMT2E Gene Therapy Project Approved
- The 2020 Spring CMTA Report
- CMTA Board Approves CMT1B Project
- Coronavirus (COVID-19) and CMT
- CMTA Event Schedule Update from CEO Amy Gray
- Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth Disease
- Coronavirus (COVID-19) Update
- CMTA Funds Cutting-Edge Gene Editing Studies for Type 2 CMT
- The 2020 Winter CMTA Report
- David Coldiron Joins CMTA Board of Directors
- A Message from Patients to Patients
- Another $500,000 Pledge to Type 2 Research!
- The 2019 Fall CMTA Report
- New Gene Therapy, Type 1/Type 4 Research Projects Approved
- New Gene Therapy Development Program for CMT2A
- $1 Million Gift Pledged to CMT Type 2 Research!
- 2019 Summer CMTA Report
- Remembering Camp Footprint
- Finding Friendship at Camp Footprint!
- Support Our Campers – Whatever It Takes!
- Camp Help Falling in Love
- 2019 Spring CMTA Report
- CMTA Unveils Updated Logo
- Type 1 CMT Gene Therapy Project Now Underway
- A Cure for Caroline and Other CMT Stories
- CMTA-Funded Research Database Identifies New Mutations
- Three Major Patient Advocacy Groups Focused on CMT Research Collaborating on FDA “Voice of the Patient” Report
- Regenacy Pharmaceuticals Announces Collaboration with the CMTA to Advance Ricolinostat for the Treatment of Hereditary Neuropathy
- Volunteer Spotlight: Amy Keller
- How Balance Walking Can Help Fitness and Living with CMT
- The CMTA Announces the Funding of a New Research Study for CMT2A
- CMTA Announces Strategic Partnership with Acceleron to Advance CMT Treatment Options
- New Mobile App Simplifies Sign-Up for Patient Registry
- 101 Practical Tips for Dealing with CMT
- New CEO Takes Helm of the CMTA
- CMTA-Funded Study on 3-D Printing Technique for Comparing CMT Heel Surgeries Named Game Changer at AAOS Meeting
- Important Alert: Neurotoxic Medication List Update
- CMTeen Dolphin Outing in PEOPLE Online
- MDA and CMTA Fund Grant to Study Gene Therapy in Charcot-Marie-Tooth Disease
- Invitae Announces Major Expansion of Its Neurology Test Offerings
- MDA and CMTA Partner to Advance Treatments and Care for Charcot-Marie-Tooth Disease
- NYSCF and CMTA Announce Largest-Ever Research Resource for Neuropathy Disorders
- STAR Launches Research for CMT4C
- Gilles Bouchard Takes Helm of CMTA Board
- CMT is on TV!
- PSA on Charcot-Marie-Tooth Disease
- The New York Stem Cell Foundation and the CMTA Enter Collaboration to Advance Neuropathies Research
Your legacy can help bring an end to CMT. Learn how a planned gift can make an impact for generations to come.
